Amorphous solid form of compounds containing S—N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cations

US11096918B2 · kind B2 · utility

Assignee

• Novartis Pharmaceuticals Corporation · US

Inventors

• Lili Feng · Pine Brook, US
• Sven Erik Godtfredsen · Chatham, US
• Paul Allen Sutton · Parsippany, US
• Mahavir Prashad · East Hanover, US
• Michael John Girgis · Richmond, US
• Bin Hu · Mesa, US
• Yugang Liu · Bound Brook, US
• Thomas J. Blacklock · Clark, US
• Piotr H. Karpinski · Lincoln Park, US

Key dates

• Filing date: Sep 23, 2019
• Grant date: Aug 24, 2021
• Expiry date: Sep 23, 2039

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K2300/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

An amorphous solid form of a compound comprising the angiotensin receptor antagonist (ARB) valsartan, the neutral endopeptidase inhibitor (NEPi) (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methylpentanoic acid ethyl ester and sodium cations is provided. This compound is useful for the treatment of hypertension and/or heart failure.